Hirano Taichi, Tsuji Takahiro, Yamasaki Hiroshi, Toyozumi Yasuo, Arima Nobuyuki, Tsuda Hiroyuki
Department of Clinical Hematology and Oncology.
Rinsho Ketsueki. 2016 Feb;57(2):171-4. doi: 10.11406/rinketsu.57.171.
Follicular lymphoma (FL) occasionally transforms into diffuse large B-cell lymphoma (DLBCL). This is generally associated with a poor prognosis, necessitating more potent chemotherapy as salvage treatment. However, de novo DLBCL, but not DLBCL transformed from FL, can be treated as primary DLBCL. We encountered a 63-year-old woman who developed DLBCL after a 9-year remission following treatment of FL. To differentiate DLBCL transformed from FL and de novo DLBCL, VDJ gene rearrangements in IgH were examined by PCR using biopsy specimens from both lymphomas. The results revealed the two lymphomas to be different clones. Thus, she was diagnosed with primary DLBCL. Therefore, routine chemotherapy and radiation therapy were conducted for the primary DLBCL with a limited stage, achieving complete remission. Treatment based on the clonality assessment of VDJ gene rearrangements is potentially useful for treating late relapse of B-cell lymphoma according to the pathological conditions of patients.
滤泡性淋巴瘤(FL)偶尔会转化为弥漫性大B细胞淋巴瘤(DLBCL)。这通常与预后不良相关,因此需要更有效的化疗作为挽救治疗。然而,原发性DLBCL,而非由FL转化而来的DLBCL,可按原发性DLBCL进行治疗。我们遇到一名63岁女性,她在FL治疗缓解9年后发生了DLBCL。为区分由FL转化而来的DLBCL和原发性DLBCL,我们使用来自两种淋巴瘤的活检标本,通过PCR检测了IgH中的VDJ基因重排。结果显示这两种淋巴瘤为不同的克隆。因此,她被诊断为原发性DLBCL。于是,对处于局限期的原发性DLBCL进行了常规化疗和放疗,实现了完全缓解。根据患者的病理情况,基于VDJ基因重排克隆性评估的治疗对于治疗B细胞淋巴瘤的晚期复发可能是有用的。